Literature DB >> 26290426

Increased prevalence of influenza B/Victoria lineage viruses during early stages of the 2015 influenza season in New South Wales, Australia: implications for vaccination and planning.

Z Jennings1, I Carter, K McPhie, J Kok, D E Dwyer.   

Abstract

During the early weeks of the 2015 Australian influenza season, influenza B accounted for 67% (821/1,234) of all positive influenza tests in New South Wales. Of 81 successive influenza B viruses characterised, 33 (41%) were from children aged < 16 years; 23/81 (28%) belonged to the B/Victoria lineage. This lineage is not contained in the southern hemisphere's 2015 trivalent influenza vaccine. The significant B/Victoria lineage activity in the southern hemisphere suggests that the quadrivalent vaccine should be considered for the northern hemisphere.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26290426     DOI: 10.2807/1560-7917.es2015.20.31.21201

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  5 in total

1.  Forty five percent of the Israeli population were infected with the influenza B Victoria virus during the winter season 2015-16.

Authors:  Sivan Sharabi; Ravit Bassal; Nehemya Friedman; Yaron Drori; Hadar Alter; Aharona Glatman-Freedman; Musa Hindiyeh; Daniel Cohen; Ella Mendelson; Tamy Shohat; Michal Mandelboim
Journal:  Oncotarget       Date:  2017-12-22

Review 2.  Literature review of the epidemiology of influenza B disease in 15 countries in the Asia-Pacific region.

Authors:  Lance Jennings; Qiu Sue Huang; Ian Barr; Ping-Ing Lee; Woo Joo Kim; Philippe Buchy; Melvin Sanicas; Bruce A Mungall; Jing Chen
Journal:  Influenza Other Respir Viruses       Date:  2018-03-07       Impact factor: 4.380

Review 3.  Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden.

Authors:  V Tisa; I Barberis; V Faccio; C Paganino; C Trucchi; M Martini; F Ansaldi
Journal:  J Prev Med Hyg       Date:  2016

4.  Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia.

Authors:  Aurélien Jamotte; Chui Fung Chong; Andrew Manton; Bérengère Macabeo; Mondher Toumi
Journal:  BMC Public Health       Date:  2016-07-22       Impact factor: 3.295

Review 5.  Evolution of Therapeutic Antibodies, Influenza Virus Biology, Influenza, and Influenza Immunotherapy.

Authors:  Urai Chaisri; Wanpen Chaicumpa
Journal:  Biomed Res Int       Date:  2018-05-28       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.